BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27083115)

  • 1. Early oncological and functional outcomes following radical treatment of high-risk prostate cancer in men older than 70 years: A prospective longitudinal study.
    Paterson C; Alashkham A; Lang S; Nabi G
    Urol Oncol; 2016 Aug; 34(8):335.e1-7. PubMed ID: 27083115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer.
    Gandaglia G; De Lorenzis E; Novara G; Fossati N; De Groote R; Dovey Z; Suardi N; Montorsi F; Briganti A; Rocco B; Mottrie A
    Eur Urol; 2017 Feb; 71(2):249-256. PubMed ID: 27209538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
    Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
    Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical outcomes of laparoscopic radical prostatectomy for high risk prostate cancer].
    Shao P; Yin C; Li J; Li P; Ju X; Lyu Q; Meng X; Hua L
    Zhonghua Wai Ke Za Zhi; 2015 Nov; 53(11):847-51. PubMed ID: 26813840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
    Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
    Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis.
    Kim KH; Lim SK; Kim HY; Shin TY; Lee JY; Choi YD; Chung BH; Hong SJ; Rha KH
    BJU Int; 2013 Jul; 112(2):216-23. PubMed ID: 23356436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
    Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
    Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial.
    Carlsson S; Jäderling F; Wallerstedt A; Nyberg T; Stranne J; Thorsteinsdottir T; Carlsson SV; Bjartell A; Hugosson J; Haglind E; Steineck G
    BJU Int; 2016 Aug; 118(2):205-12. PubMed ID: 26867018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological and oncological outcomes of elderly men with clinically localized prostate cancer.
    Mitsuzuka K; Koie T; Narita S; Kaiho Y; Yoneyama T; Tsuchiya N; Kakoi N; Kawamura S; Tochigi T; Ohyama C; Habuchi T; Arai Y
    Jpn J Clin Oncol; 2013 Dec; 43(12):1238-42. PubMed ID: 24068712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
    Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.
    Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC
    Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.